Literature DB >> 476011

Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels.

A J Keller, A Chirnside, S J Urbaniak.   

Abstract

Five patients with immunopathologic renal disease, 12 with malignant paraproteinaemia and one with myasthenia gravis underwent a total of 179 plasma exchanges on a continuous flow cell separator. Replacement fluids devoid of coagulation factors were used in 160 exchanges while 19 exchanges were replaced with Fresh Frozen Plasma. Coagulation screening was done immediately before and 30 min after each plasma exchange. Plasma fibrinogen concentrations fell to a mean of 25% of initial levels during individual exchanges. Sequential reduction to 10.7% was observed after five consecutive daily exchanges and in one patient fell to 1.2% after 10 daily exchanges. Low levels of fibrinogen could be maintained with daily or alternate daily exchanges. Platelet counts fell to a mean of 50% of pre-exchange levels during individual exchanges. Consecutive daily exchanges resulted in mean reductions to 20.7% after 5 d, but further reductions were not observed with longer periods of exchange. Platelet counts recovered to pre-exchange values during exchange intervals of 2 or more days. Mild clinical bleeding episodes, probably related to low platelet counts, occurred in one exchange in each of three patients. Haemostasis was rapidly achieved in these patients by infusions of platelet concentrates. Coagulation screening, including prothrombin ratio, thrombin time, reptilase time and partial thromboplastin time with kaolin showed progressively greater abnormalities as the intervals between exchanges shortened. The low incidence of clinical haemorrhagic episodes, three of 179 exchanges (2.2%), despite markedly abnormal coagulation parameters, emphasize the safety of the procedure even in moribund patients. We conclude that the use of FFP in intensive exchange programmes solely for the prevention of spontaneous haemorrhagic phenoma is unjustified.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476011     DOI: 10.1111/j.1365-2141.1979.tb01172.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Plasmapheresis: technique and complications.

Authors:  P M Reimann; P D Mason
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 2.  Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review.

Authors:  Kimberly L Hodulik; Adam G Root; Leila S Ledbetter; Oluwatoyosi A Onwuemene
Journal:  Transfusion       Date:  2019-02-14       Impact factor: 3.157

3.  Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange.

Authors:  G R Thompson; J P Miller; J L Breslow
Journal:  Br Med J (Clin Res Ed)       Date:  1985-12-14

4.  Elimination kinetics of plasma exchange.

Authors:  F Keller; K Wagner; U Faber; J Scholle; H H Neumayer; M Maiga; G Schultze; G Offermann; M Molzahn
Journal:  Klin Wochenschr       Date:  1983-11-15

5.  Complications of plasma exchange in patients with neurological diseases.

Authors:  T Henze; H W Prange; J Talartschik; K W Rumpf
Journal:  Klin Wochenschr       Date:  1990-12-04

6.  The effects of repeated automated plasmapheresis in goats (Capra hircus) in response to vaccination with purified influenza hemagglutinin proteins.

Authors:  Willie D Taylor; Gregory L Langham; James L Weed; Thomas Rowe; Wei Song; Kristin A Isenberg; Xiyan Xu; David E Wentworth; George Lathrop; Nathaniel Powell
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

7.  Apheresis Efficacy and Tolerance in the Setting of HLA-Incompatible Kidney Transplantation.

Authors:  Johan Noble; Antoine Metzger; Hamza Naciri Bennani; Melanie Daligault; Dominique Masson; Florian Terrec; Farida Imerzoukene; Beatrice Bardy; Gaelle Fiard; Raphael Marlu; Eloi Chevallier; Benedicte Janbon; Paolo Malvezzi; Lionel Rostaing; Thomas Jouve
Journal:  J Clin Med       Date:  2021-03-23       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.